Pulse nav.journalClub 활발한 토론 트렌드 탐색 질문 연구자

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

개인정보 처리방침

홈 탐색 nav.journalClub 트렌드

⌘+K

Novel protein biomarkers for risk stratification and personalized medicine | Synapse

March 26, 2026

Novel protein biomarkers for risk stratification and personalized medicine

Key Points

The research aims to identify urinary biomarkers that reflect the biological impact of different therapies in chronic kidney disease (CKD).
Analyzing urinary clusterin and uEGF as biomarkers
Comparing these biomarkers with albuminuria measurements
Investigating their role in assessing tubular injury and repair in CKD
Urinary clusterin and uEGF reflect distinct intrarenal pathways activated by specific therapies
These biomarkers provide additional insights beyond albuminuria
They demonstrate potential for enhanced risk stratification in CKD patients

Abstract

Urinary clusterin and uEGF are mechanism-informed pharmacodynamic biomarkers reflecting distinct intrarenal pathways engaged by ERA and SGLT2i therapy, respectively. These biomarkers complement albuminuria by capturing tubular injury and repair, providing a more comprehensive biological assessment of treatment effects and heterogeneity in CKD.

Like

Bookmark

Share

Cite This Study

Moedt et al. (Fri,) studied this question.

synapsesocial.com/papers/69c4cd73fdc3bde448919c44 https://doi.org/https://doi.org/10.1093/ndt/gfag068

Like

Bookmark

Share